Cullinan Oncology

Edit info

Founded: 2016

Location: Cambridge, MA

Employee range: 11 - 50

Clinical stage: Clin2

Therapy area: NSCLC

Drug types: ONC

Lead product: Zipalertinib

Funding: $287M IPO Jan 2021; $98M B Jun 2020; $150M A Oct 2017

cullinanoncology.com

linkedin.com

job board

Drug notes:

CLN-049 Clin1 AML, MDS; CLN-619 Clin1 oncology; CLN-617 Clin0 oncology; CLN-978 Clin1 B-cell NHL; 2 undisclosed programs RD oncology, undisclosed

About:

Based in Cambridge, Massachusetts, Cullinan Oncology is committed to creating novel solutions for cancer patients. They are developing a wide range of therapeutics, including small molecules, monoclonal antibodies, kinase inhibitors, and protein degraders. Their team has varied backgrounds with expertise in protein engineering, drug discovery, immunology, and oncology. Cullinan Oncology was founded in 2017 by K. Dane Wittrup and Patrick Baeuerle.